Your browser is no longer supported. Please, upgrade your browser.
CGEN Compugen Ltd. monthly Stock Chart
Compugen Ltd.
Index- P/E- EPS (ttm)-0.37 Insider Own12.00% Shs Outstand81.27M Perf Week7.47%
Market Cap1.46B Forward P/E- EPS next Y-0.46 Insider Trans0.00% Shs Float- Perf Month20.45%
Income-26.30M PEG- EPS next Q-0.09 Inst Own40.60% Short Float- Perf Quarter25.90%
Sales- P/S- EPS this Y-5.10% Inst Trans4.23% Short Ratio4.40 Perf Half Y92.86%
Book/sh1.59 P/B11.04 EPS next Y-24.30% ROA-27.10% Target Price19.25 Perf Year361.84%
Cash/sh- P/C- EPS next 5Y- ROE-32.50% 52W Range3.41 - 17.85 Perf YTD194.46%
Dividend- P/FCF- EPS past 5Y-13.10% ROI- 52W High-1.68% Beta2.74
Dividend %- Quick Ratio17.00 Sales past 5Y- Gross Margin- 52W Low414.66% ATR1.08
Employees61 Current Ratio17.00 Sales Q/Q- Oper. Margin- RSI (14)63.15 Volatility6.46% 6.87%
OptionableYes Debt/Eq0.00 EPS Q/Q21.00% Profit Margin- Rel Volume1.40 Prev Close16.28
ShortableYes LT Debt/Eq0.00 EarningsJul 30 BMO Payout- Avg Volume1.44M Price17.55
Recom1.50 SMA2013.09% SMA5015.26% SMA20071.89% Volume2,013,420 Change7.80%
May-26-20Resumed JMP Securities Mkt Outperform $18
May-13-20Initiated Stifel Buy $19
May-07-20Initiated SVB Leerink Outperform
Apr-22-20Initiated ROTH Capital Buy $28
Mar-24-20Initiated SunTrust Buy $16
Jan-16-20Initiated Cantor Fitzgerald Overweight $10
Mar-29-18Initiated Oppenheimer Outperform
Feb-01-16Resumed Oppenheimer Outperform
Oct-15-15Initiated FBR Capital Outperform $14
Apr-23-15Resumed Jefferies Buy $11
Apr-21-15Initiated Oppenheimer Outperform $11
Feb-07-14Initiated MLV & Co Buy $14
Dec-28-09Reiterated Cantor Fitzgerald Buy $5 → $12
Jul-29-09Initiated Cantor Fitzgerald Buy $6.50
Jul-31-20 02:31AM  
Jul-30-20 07:00AM  
Jul-16-20 07:00AM  
Jul-14-20 03:35PM  
Jun-22-20 02:40PM  
Jun-01-20 07:00AM  
May-27-20 07:00AM  
May-20-20 07:02AM  
May-18-20 08:46AM  
May-13-20 09:48AM  
May-08-20 02:39PM  
May-06-20 10:00PM  
May-04-20 11:57AM  
Apr-30-20 12:00PM  
Apr-27-20 06:05AM  
Apr-24-20 10:50AM  
Apr-23-20 07:00AM  
Apr-22-20 08:22AM  
Apr-20-20 07:00AM  
Apr-14-20 07:00AM  
Apr-06-20 07:00AM  
Mar-17-20 07:00AM  
Mar-12-20 06:05AM  
Mar-11-20 04:01PM  
Mar-10-20 10:00AM  
Mar-09-20 07:10AM  
Feb-20-20 07:05AM  
Feb-10-20 07:58AM  
Feb-07-20 07:00AM  
Feb-04-20 07:00AM  
Jan-29-20 08:30AM  
Jan-16-20 07:47PM  
Jan-09-20 07:00AM  
Jan-08-20 07:00AM  
Dec-23-19 08:04PM  
Dec-20-19 07:00AM  
Dec-17-19 09:11AM  
Dec-12-19 11:56AM  
Dec-11-19 09:04AM  
Dec-03-19 12:00PM  
Nov-11-19 07:00AM  
Nov-06-19 08:30AM  
Nov-05-19 08:06AM  
Nov-04-19 07:00AM  
Oct-28-19 07:00AM  
Oct-12-19 09:28AM  
Oct-10-19 09:00AM  
Oct-02-19 07:00AM  
Sep-19-19 07:00AM  
Aug-28-19 12:52PM  
Aug-22-19 12:01PM  
Aug-14-19 12:18PM  
Aug-13-19 11:53AM  
Aug-08-19 11:20AM  
Aug-05-19 04:16PM  
Jul-22-19 07:00AM  
Jul-16-19 07:00AM  
Jul-02-19 07:00AM  
Jun-27-19 03:07PM  
Jun-26-19 09:00AM  
Jun-12-19 09:14AM  
Jun-03-19 07:00AM  
May-23-19 09:00AM  
May-22-19 07:00AM  
May-20-19 06:08PM  
May-06-19 07:00AM  
Apr-18-19 09:00AM  
Apr-03-19 07:00AM  
Mar-26-19 08:40AM  
Mar-12-19 07:46AM  
Mar-08-19 10:04AM  
Mar-07-19 09:09AM  
Mar-05-19 07:00AM  
Mar-01-19 07:00AM  
Feb-26-19 02:00AM  
Feb-14-19 07:00AM  
Jan-22-19 07:00AM  
Jan-16-19 07:07AM  
Jan-14-19 07:00AM  
Nov-23-18 08:20AM  
Nov-13-18 07:00AM  
Nov-07-18 08:20AM  
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.